Relmada Therapeutics, Inc

Get Full Access

Description

  • Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmadas product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmadas approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com
  • location

    Headquarters:757 Third Avenue , New York, New York, United States

    More
  • Relmada Therapeutics, Inc phone

    Phone Number: +1 212-702-7163

  • Relmada Therapeutics, Inc website

    Website: https://www.relmada.com

  • Relmada Therapeutics, Inc employees

    Employees:19

  • Relmada Therapeutics, Inc revenue

    Revenue:$1 - 10M

  • Relmada Therapeutics, Inc legal name

    Legal Name:Relmada Therapeutics, Inc

  • Relmada Therapeutics, Inc's Social Media

    Relmada Therapeutics, Inc linkedin Relmada Therapeutics, Inc facebook Relmada Therapeutics, Inc twitter
  • done Is this data correct?
  • |  NAICS Code: 517919  |

    Show More
Person level website identification

CEO for Relmada Therapeutics, Inc

Sergio Traversa

Chief Executive Officer

Person level website visitor identification

Sell more in less time!

Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!

View Employees

Maged Shenouda

Chief Financial Officer

Cornelia Kroeger

Senior Vice President Operations

Daisy Ng-Mak

Vice President, Head Of Value Strategy And Global Heor

Marc De Somer Scd

Senior Vice President Clinical Development And Safety, Relmada Therapeutics

Paul Kelly

Director

Frequently Asked Questions regarding Relmada Therapeutics, Inc

  • Where are Relmada Therapeutics, Inc's Headquarters?

    Relmada Therapeutics, Inc's Headquarters are in 757 Third Avenue ,New York,New York,United States

  • What is Relmada Therapeutics, Inc's phone number?

    Relmada Therapeutics, Inc's phone number is +1 212-702-7163

  • What is Relmada Therapeutics, Inc's official website?

    Relmada Therapeutics, Inc's official website is https://www.relmada.com

  • What is Relmada Therapeutics, Inc's Revenue?

    Relmada Therapeutics, Inc's revenue is $1 - 10M

  • What is Relmada Therapeutics, Inc's NAICS code?

    Relmada Therapeutics, Inc's NAICS code is 517919

  • How many employees are working in Relmada Therapeutics, Inc

    Relmada Therapeutics, Inc has 19 employees

  • What is Relmada Therapeutics, Inc's Industry?

    Relmada Therapeutics, Inc is in the industry of Pharmaceuticals

  • Who is Relmada Therapeutics, Inc's CEO?

    Relmada Therapeutics, Inc's CEO is Sergio Traversa

Company Directory